References
- Alanagreh L, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens. 2020;9:331. Available from: https://pubmed.ncbi.nlm.nih.gov/32365466/
- Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. J Biomol Struct Dyn. 2020;1–9. DOI:10.1080/07391102.2020.1761882
- Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202‐2205. Available from: https://pubmed.ncbi.nlm.nih.gov/32217834/
- D’Alessandro S, Scaccabarozzi D, Signorini L, et al. The use of antimalarial drugs against viral infection. Microorganisms. 2020 Jan 8;8(1):85. Available from: https://pubmed.ncbi.nlm.nih.gov/31936284/
- Conforti C, Giuffrida R, Zalaudek I, et al. Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak [published online ahead of print, 2020 Apr 20]. Dermatol Ther. 2020;e13437. DOI:10.1111/dth.13437
- Farouk A, Salman S. Dapsone and doxycycline could be potential treatment modalities for COVID-19 [published online ahead of print, 2020 Apr 22]. Med Hypotheses. 2020;140:109768.
- Gendrot M, Andreani J, Jardot P, et al. In vitro antiviral activity of Doxycycline against SARS-COV-2. 2020. Available from: https://www.mediterranee-infection.com/in-vitro-antiviral-activity-of-doxycycline-against-sars-cov-2/
- Roden DM, Harrington RA, Poppas A, et al. Considerations for drug interactions on QTc in exploratory COVID-19 (Coronavirus disease 2019) treatment [published online ahead of print, 2020 Apr 8]. Circulation. 2020. Available from: https://pubmed.ncbi.nlm.nih.gov/32267732/